Company news

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) news

Eledon Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 5, 2026: Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology…

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) news

Press releases & updates

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results